 |
|
|
| |
Lenacapavir (GS-6207) Sustained Delivery Formulation Supports 6-Month Dosing Interval
|
| |
| |
IAC 2020 Virtual July 6-10
Reported by Jules Levin
Rebecca Begley, Justin Lutz, Martin Rhee, Hadas Dvory-Sobol, Anna Chiu, Steve K. West,
Jessica Corpus, John Ling, Polina German
Gilead Sciences, Inc., Foster City, California, USA
|
| |
|
|
|
|
|
